Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination with antibiotics)
* Gastrointestinal bleeding prophylaxis
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Symptomatic GERD:** 40 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions:** Start with 40 mg orally or intravenously twice daily. Doses may be increased to 240 mg daily depending on clinical response.
* **H. pylori Eradication (Triple Therapy):** 40 mg orally twice daily for 7-14 days in combination with clarithromycin and amoxicillin or metronidazole.
* **H. pylori Eradication (Quadruple Therapy):** 40 mg orally once daily for 10-14 days in combination with bismuth subsalicylate, metronidazole, and tetracycline.
## Pediatric Dosing
* **1 to <5 years:** 10 mg orally once daily for GERD.
* **5 to <12 years:** 20 mg orally once daily for GERD.
* **12 to 16 years:** 40 mg orally once daily for GERD.
*Note: Dosing for erosive esophagitis in pediatrics varies by age and weight. Consult specific guidelines.*
## Dose Adjustments
No dose adjustment is generally necessary for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, vomiting, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, lupus erythematosus (cutaneuous and systemic).
## Key Drug Interactions
* **Antiretrovirals (e.g., nelfinavir, atazanavir):** Reduced plasma concentrations. Avoid concomitant use or monitor closely.
* **Clopidogrel:** May decrease the antiplatelet effect. Consider alternatives or closely monitor for cardiovascular events.
* **Methotrexate:** May increase methotrexate levels. Consider temporary pantoprazole discontinuation.
* **Drugs dependent on gastric pH for absorption (e.g., ketoconazole, itraconazole, iron salts):** May decrease absorption.
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor serum magnesium levels, especially with prolonged use (>3 months) or concomitant diuretic use.
* Consider vitamin B12 levels with long-term therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Administer 30-60 minutes before a meal.
* For intravenous administration, reconstitute and dilute according to manufacturer instructions. Infuse over at least 15 minutes.
* Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
* Discontinuation of PPIs should ideally be gradual to prevent acid rebound.
***
*Disclaimer: This information is intended for clinical decision support and does not replace comprehensive drug information resources or institutional protocols. Always verify current prescribing information with the official product monograph and relevant clinical guidelines before initiating therapy.*
